![]() |
市場調査レポート
商品コード
1451694
男性不妊市場レポート:検査タイプ、治療、流通チャネル、エンドユーザー、地域別、2024-2032Male Infertility Market Report by Test Type, Treatment, Distribution Channel, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
男性不妊市場レポート:検査タイプ、治療、流通チャネル、エンドユーザー、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2~3営業日
|
世界の男性不妊市場規模は2023年に40億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて4.79%の成長率(CAGR)を示し、2032年までに62億米ドルに達すると予測しています。男性不妊の有病率の増加、親になるのが遅れる傾向の高まり、著しい技術進歩、ライフスタイルの進化、不妊症に対する意識の高まり、生殖補助医療技術の合法化などが市場を後押しする主な要因です。
男性不妊とは、男性の生殖器系に関連する要因のために、男性が女性のパートナーを妊娠させることができない状態を指します。多くの場合、精子の生産、質、または分娩に問題があることに起因します。男性不妊の要因としては、精子数の減少、精子の形状や運動率の異常、ホルモンバランスの乱れ、遺伝的要因、精索静脈瘤(陰嚢の静脈の肥大)のような特定の病状などが挙げられます。また、過度の飲酒、喫煙、薬物の使用、肥満などの生活習慣も男性不妊の一因となります。
世界的に男性不妊の罹患率が上昇していることは、市場の重要な促進要因です。ライフスタイルの変化、環境汚染物質、ストレス関連因子がこの増大する懸念の一因となっており、診断・治療ソリューションの必要性が高まっています。さらに、キャリアの目標やその他の人生の願望を追求するために子作りを遅らせるという動向は、男性の年齢関連の不妊問題の高まりにつながっています。このことが、男性不妊治療や生殖補助医療技術の需要に拍車をかけています。これ以外にも、教育キャンペーンやデジタルリソースのおかげで、不妊問題に対する意識が高まり、不妊問題のために医療支援を求める男性が増加しており、市場の成長を促進しています。このほか、座りがちな生活、食生活の乱れ、環境毒素への曝露の増加が精子の質と量の低下に関連しています。こうした要因に対する意識が高まるにつれ、こうした影響を打ち消すための介入策や治療法に対する需要が高まっています。これに伴い、医療技術の進歩により、男性不妊の診断法や治療法の精度が向上しています。精子DNA断片化解析や高度な精子選択法などの革新的技術により、治療成績が向上しています。
男性不妊の有病率の増加
座りがちなライフスタイル、環境汚染物質への曝露、高いストレスレベルなど、多くの要因が総体的に男性の不妊症の増加に寄与しています。これらの要因は、精子の生産、質、運動率に悪影響を及ぼす可能性があります。男性不妊の蔓延が認識されるにつれ、正確な診断と効果的な治療法に対する需要が高まっています。夫婦は、これらの懸念に対処するために医学的専門知識を求めており、不妊治療サービスの診察と採用の増加に繋がっています。
子育て延期の動向の高まり
社会規範やキャリア志向の進化により、子育てを遅らせる傾向が勢いを増しています。しかし、加齢の進行は、精子の質の低下やDNAの断片化の増加など、男性の生殖能力の低下と関連しています。この現象は、男性の加齢に関連した不妊の課題を生んでいます。その結果、男性不妊市場では、人生の後半に家庭を築きたいと願う高齢男性の間で、妊孕性の温存や治療オプションに対する需要が急増しています。この動向は、この層特有の要件に対応する専門的介入の必要性を強調しています。
重要な技術的進歩
精子DNA断片化解析のような革新的技術により、精子の質をより包括的に評価することが可能になった。さらに、磁気活性化細胞選別(MACS)のような高度な精子選別法は、受精成功の可能性を高める。これらの技術は、不妊の根本的な原因を特定する精度を向上させ、ヘルスケア専門家に治療計画を調整するための幅広いツールを提供します。技術が進化し続けるにつれて、治療成績が大幅に改善される可能性があり、患者により効果的で個別化された解決策を提供することで、男性不妊市場の成長に貢献します。
The global male infertility market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.79% during 2024-2032. The increasing prevalence of male infertility, rising trend of delayed parenthood, significant technological advancements, evolving lifestyles, increasing awareness about infertility, and legalization of assisted reproductive technologies are some of the major factors propelling the market.
Male infertility refers to the condition in which a man is unable to impregnate a female partner due to factors related to his reproductive system. It is often attributed to issues with sperm production, quality, or delivery. Factors that can contribute to male infertility include low sperm count, abnormal sperm shape or motility, hormonal imbalances, genetic factors, and certain medical conditions like varicocele (enlarged veins in the scrotum). Lifestyle factors such as excessive alcohol consumption, smoking, drug use, and obesity can also play a role in male infertility.
The rising incidence of male infertility worldwide is a significant driver for the market. Changing lifestyles, environmental pollutants, and stress-related factors contribute to this growing concern, necessitating the need for diagnostic and treatment solutions. Additionally, the trend of delaying parenthood to pursue career goals and other life aspirations has led to higher age-related fertility issues among men. This has spurred the demand for male infertility treatments and assisted reproductive technologies. Other than this, increasing awareness about fertility issues, thanks to educational campaigns and digital resources, has prompted more men to seek medical assistance for infertility problems, thus driving the market growth. Besides this, sedentary lifestyles, poor dietary habits, and increased exposure to environmental toxins have been linked to declining sperm quality and quantity. As individuals become more conscious of these factors, the demand for interventions and treatments to counteract these effects has risen. In line with this, advancements in medical technologies have improved the accuracy of diagnostic procedures and treatment options for male infertility. Innovative techniques such as sperm DNA fragmentation analysis and advanced sperm selection methods have enhanced treatment outcomes.
Increasing Prevalence of Male Infertility
A multitude of factors, including sedentary lifestyles, exposure to environmental pollutants, and high stress levels, have collectively contributed to a rise in fertility issues among men. These factors can adversely affect sperm production, quality, and motility. As the prevalence of male infertility becomes more recognized, there is a growing demand for accurate diagnostics and effective treatment options. Couples are seeking medical expertise to address these concerns, leading to increased consultations and adoption of fertility services.
Rising Trend of Delayed Parenthood
The trend of delaying parenthood has gained momentum due to evolving societal norms and career aspirations. However, advancing age is associated with a decline in male fertility, including decreased sperm quality and increased DNA fragmentation. This phenomenon has given rise to age-related fertility challenges among men. As a result, the male infertility market is witnessing a surge in demand for fertility preservation and treatment options among older men who wish to start families later in life. This trend emphasizes the need for specialized interventions that cater to the unique requirements of this demographic.
Significant Technological Advancements
Innovative techniques such as sperm DNA fragmentation analysis enable a more comprehensive assessment of sperm quality. Additionally, advanced sperm selection methods, such as magnetic-activated cell sorting (MACS), enhance the chances of successful fertilization. These technologies offer improved accuracy in identifying underlying causes of infertility and provide healthcare professionals with a wider range of tools to tailor treatment plans. As technology continues to evolve, it has the potential to significantly improve outcomes and contribute to the growth of the male infertility market by providing patients with more effective and personalized solutions.
IMARC Group provides an analysis of the key trends in each segment of the global male infertility market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on test type, treatment, distribution channel and end user.
Sperm Agglutination
DNA Fragmentation Technique
Oxidative Stress Analysis
Computer Assisted Semen Analysis
Sperm Penetration Assay
Others
DNA fragmentation technique dominates the market
The report has provided a detailed breakup and analysis of the market based on the test type. This includes sperm agglutination, DNA fragmentation technique, oxidative stress analysis, computer assisted semen analysis, sperm penetration assay, and others. According to the report, DNA fragmentation technique represented the largest segment.
The DNA fragmentation technique stands as the largest segment in the market breakup by test type due to its ability to offer deeper insights into male infertility. This technique assesses DNA damage within sperm, providing crucial information about sperm quality. As a result, it has gained prominence in accurately diagnosing the underlying causes of male infertility, guiding tailored treatment approaches for better outcomes.
Medication
Assisted Reproductive Technology and Varicocele Surgery
Assisted reproductive technology and varicocele surgery hold the largest market share
A detailed breakup and analysis of the market based on the treatment has also been provided in the report. This includes medication and assisted reproductive technology and varicocele surgery. According to the report, assisted reproductive technology and varicocele surgery accounted for the largest market share.
ART, encompassing techniques like in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), offers couples the opportunity to overcome various fertility challenges, including male factor infertility. The success rates and advancements in ART have positioned it as a leading choice. Varicocele surgery, on the other hand, is a well-established surgical intervention to treat varicoceles, which are dilated veins in the scrotum that can impede sperm production and quality. By surgically correcting varicoceles, blood flow is improved, potentially enhancing sperm production and motility. This procedure has demonstrated positive outcomes in restoring fertility potential. The popularity of these treatments arises from their proven efficacy, leading to their prominent status in the market's treatment landscape.
Hospitals Pharmacies
Pharmacies and Drug Stores
Online Pharmacies
Male infertility products are majorly distributed through hospital pharmacies
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospitals pharmacies, pharmacies and drug stores, and online pharmacies. According to the report, hospitals pharmacies represented the largest segment.
Hospitals offer a range of specialized diagnostic facilities, medical expertise, and treatment options under one roof. This makes them a primary destination for patients seeking comprehensive evaluation, consultations with fertility specialists, and advanced interventions, including assisted reproductive technologies (ART) and surgical procedures. Pharmacies play a crucial role by providing access to prescription medications, supplements, and fertility-related products that support male reproductive health. They serve as convenient points of access for patients to obtain prescribed medications for fertility treatment and management. Additionally, pharmacies offer a discreet environment where individuals can access over-the-counter fertility supplements and products that complement treatment plans.
Hospitals and Clinics
Fertility Centers
Research Institutes
Others
Fertility centers account for the majority of the share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals and clinics, fertility centers, research institutes, and others. According to the report, fertility centers accounted for the largest market share.
These centers are dedicated to providing a wide range of services specifically tailored to individuals and couples facing fertility challenges. Fertility centers house a team of experienced reproductive endocrinologists, urologists, embryologists, and other specialists who collectively offer advanced diagnostic evaluations, personalized treatment plans, and assisted reproductive technologies (ART) under one roof. The multidisciplinary nature of fertility centers allows for a holistic approach to male infertility, encompassing medical assessments, laboratory analyses, and innovative treatments. These centers offer a supportive environment that addresses the emotional and physical aspects of fertility struggles. The availability of state-of-the-art technologies, cutting-edge procedures, and a comprehensive understanding of male reproductive health positions fertility centers as the preferred choice for individuals seeking expert guidance and successful outcomes in their journey towards overcoming male infertility.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Europe exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.
The region possesses a well-developed healthcare infrastructure, including advanced medical facilities, fertility clinics, and research institutions, enabling efficient diagnosis and treatment of male infertility. Moreover, changing socio-cultural dynamics have led to increased awareness and acceptance of fertility issues, prompting more individuals and couples to seek medical intervention. European countries also prioritize reproductive health and offer comprehensive healthcare coverage, making fertility treatments more accessible to a larger population. The aging population across the region contributes to a growing demand for assisted reproductive technologies (ART) as delayed parenthood becomes more common. Furthermore, the strong presence of Europe in medical research and development fuels innovations in male infertility treatments, attracting both domestic and international patients seeking cutting-edge solutions.
Leading companies are investing significantly in research and development to create new and improved diagnostic tools, treatments, and technologies for male infertility. This includes developing innovative sperm analysis techniques, medications, and assisted reproductive technologies to enhance treatment outcomes. Additionally, key players often collaborate with academic institutions, research organizations, and healthcare providers to exchange knowledge, share insights, and drive advancements in male infertility diagnostics and treatments. These collaborations foster a synergistic approach to tackling complex challenges and developing comprehensive solutions. Other than this, recognizing the importance of raising awareness about male infertility, industry leaders are actively involved in educational initiatives. They offer information through online platforms, seminars, and healthcare professional training, aimed at increasing understanding of the condition and encouraging timely interventions. Moreover, key players engage in strategic expansion efforts to tap into emerging markets with growing demand for male infertility treatments. By extending their reach, they aim to provide access to advanced diagnostics and therapies to a wider patient population.
Andrology Solutions
CinnaGen Co.
Halotech DNA
SCSA Diagnostics Inc.
Vitrolife
Zydus Lifesciences Limited
Intas Pharmaceuticals Ltd.
Endo International plc.
Andrology Solutions has made recent advancements in the field of male infertility, including improvements in the understanding and management of male factor infertility. It has also worked on developing panels for male infertility genes, which have achieved high accuracy in diagnosing copy number variants (CNVs). These advancements contribute to the diagnosis and treatment of male infertility, allowing for more effective interventions and improved outcomes.
Halotech DNA, a leading international biotech company based in Madrid, has introduced innovative DNA fragmentation analysis systems for evaluating sperm quality. These systems are designed to assess the level of DNA damage in sperm cells, which can be a contributing factor to male infertility. This analysis helps in identifying the underlying causes of infertility and guides the selection of appropriate treatment options.
In 2022, SCSA Diagnostics Inc. developed a test called the SCSA (Sperm Chromatin Structure Assay), which is used to evaluate sperm chromatin structure and DNA strand breaks. The SCSA test is a two-fold simultaneous flow cytometry measure of the extent of sperm nuclear single (ss) and double (ds) strand DNA breaks. This test provides unique information about male infertility by assessing the integrity of sperm DNA, which is crucial for successful fertilization and embryo development.